Article
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trial
2023-07-27
Abstract excerpt
<title>Abstract</title> <p>In this phase 2 REBNOBATE trial, we evaluated regorafenib-nivolumab as front-line treatment for unresectable hepatocellular carcinoma (uHCC). Patients (<italic>n</italic> = 42) received nivolumab 480 mg every 4 weeks, and regorafenib 80 mg daily (3-weeks on/1-week off schedule). Single-cell RNA sequencing was performed using peripheral blood mononuclear cells from early progressors (pro...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d8674af4-910f-50eb-8760-1b37c5848471
- DOI
- 10.21203/rs.3.rs-3113386/v1